What's new in the prevention of stroke?;Qualcosa di nuovo nella prevenzione dell'ictus?

Italian Heart Journal Supplement

Volumn 4, Issue 12, 2003, Pages 958-964

  Antonicelli, Roberto ^a   Germanò, Giuseppe ^b  

^a INRCA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ACE inhibitors; Angiotensin; Hypertension; Stroke

Indexed keywords

ANGIOTENSIN II;

AGED; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; REVIEW;

AGED; ANGIOTENSIN II; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HUMANS;

EID: 6944250149     PISSN: 11294728     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. SPREAD Stroke Prevention And Educational Awareness Diffusion 2001. Ictus cerebrale: linee guida italiane (stesura febbraio 2001). Milano: Publ Catel.
2. Kannel WB, Wolf PA, Verter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke: the Framingham Study. JAMA 1970; 214: 301-10.
3. Wolf PA, D'Agostino RB, BelangerAJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991;22:312-8.
4. Qureshi Al, Suri MF, Mohammad Y, Guterman LR, Hopkins LN. Isolated and borderline isolated systolic hypertension relative to long-term risk and type of stroke. A 20-year follow-up of the National Health and Nutrition Survey. Stroke 2002; 33:2781-8.
5. The Italian Longitudinal Study on Aging Working Group. Prevalence of chronic diseases in older Italians: comparing self-reported and clinical diagnoses. Int J Epidemiol 1997; 26: 995-1002.
6. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease. Part I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
7. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systemic review and meta-analysis. JAMA 1997; 277: 739-45.
8. Insua JT, Sacks HS, Lau TS, et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994; 121:355-62.
9. MacMahon S. Blood pressure and the prevention of stroke. J Hypertens Suppl 1996; 14: S39-S46.
10. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-72.
11. Neal B, MacMahon S, Chapman N, for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-Iowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955-64.
12. Staessen JA, Fagard R, Thijs L, et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-64.
13. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
14. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
15. Opie LH, Schall R. Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. J Am Coll Cardiol 2002; 39: 315-22.
16. ALLHAT officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
17. Byyny RL, Merrill DD, Bradstreet TE, Sweet CS. An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension. Cardiovasc Drugs Ther 1996; 10: 313-9.
18. Zanchetti A, Omboni S, for the Italian Candesartan Study Group. Comparison of candesartan versus enalapril in essential hypertension. Am J Hypertens 2001; 14: 129-34.
19. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-50.
20. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodip-ine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-5.
21. Schiffrin EL, for the Canadian Institutes of Health Research Multidisciplinary Research Group on Hypertension. Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens 2002; 15 (Part 2): 115S-122S.
22. Dahlöf B, Devereux RB, Kjeldsen SE, et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
23. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
24. Hansson L, Lindholm LH, Ekbom T, et al, for the STOP-Hy-pertension-2 Study Group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.
25. Hansson L, Lindholm LH, Niskanen L, et al, for the Captopril Prevention Project (CAPPP) Study Group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
26. Hansson L, HednerT, Lund-Johansen P, et al, for the NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65.
27. Messerli FH. The LIFE study: the straw that should break the camel's back. Eur Heart J 2003; 24: 487-9.
28. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903-7.
29. Wink K. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? Curr Hypertens Rep 2003; 5:221-4.
30. Gorelick PB. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review. Stroke 2002; 33: 862-75.
31. Rossi GP, Rossi A, Sacchetto A, et al. Hypertensive cerebrovascular disease and the renin-angiotensin system. Stroke 1995; 26: 1700-6.
32. Volpe M, Savoia C, De Paolis P, Ostrowska B, Tarasi D, Rubattu S. The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol 2002; 13 (Suppl 3): S173-S178.
33. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 1-5.
34. Svensson P, deFaire U, Sleight P, Yusuf S, Ostergren J. Comparative effect of ramipril on ambulatory and office blood pressure - A HOPE substudy. Hypertension 2001; 38: E28-E32.
35. Ennezat PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2000; 2: 258-62.
36. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982; 4: 966-72.
37. Shiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002; 113: 409-18.
38. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5.
39. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255-64.
40. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72.
41. Lindholm LH, Ibsen H, Dahlof B, et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10.
42. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention For Endpoint reduction (LIFE) substudy. JAMA 2002; 288: 1491-8.
43. Sica DA, Schoolwerth AC. Uric acid and losartan. Part 1. Curr Opin Nephrol Hypertens 2002; 11:475-82.
44. Wurzner G, Gerster JC, Chiolero A, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19: 1855-60.
45. Krämer C, Sunkomat J, Witte J, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan. Role of the active metabolite EXP3179. Circ Res 2002; 90: 770-6.
46. Jiménez AM, Montón M, García R, et al. Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. Cardiovasc Pharmacol 2001; 37: 406-12.